Stefan Klaus Barta MD MD, MS, MRCP(UK)

PubMed

• Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome.
  Omar Elghawy, Jonathan H Sussman, Austin G Yang, Colin J Thomas, Jordan S Carter
  JAMA Dermatology. 2025-04-02
• Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP.
  Vincent Ni, Sunita D Nasta, Stefan K Barta, Stephen J Schuster, Elise A Chong
  Haematologica. 2025-04-01
• Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Rec...
  Luke Maillie, Sunita D Nasta, Jakub Svoboda, Stefan K Barta, Elise A Chong
  Transplantation and Cellular Therapy. 2025-04-01

Journal Articles

• Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib  
  Stefan Barta, MD, Clinical Pharmacokinetics
• Synergy of Sequential Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti- CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine M...  
  Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A, Leukemia & Lymphoma 2012 Oct; 53(10):1999-2003
• A phase I study of a combination of anti-CD19 and anti- CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.  
  Schindler J, Gajavelli S, Ravandi F, Shen YM, Parekh S, Braunschweig I, Barta S, Ghetie V, Vitetta E, Verma A, Br J Haematol 2011;154:471-6. PMID 21732928
• Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma.  
  Barta SK, Yahalom J, Shia J, Hamlin PA, Clin Lymphoma Myeloma. 2006 Jul;7(1):77-82. PMID: 16879775
• Mood Changes following Acute Tryptophan Depletion in Healthy Adults.  
  Schmeck K, Sadigorsky S, Englert E, Demisch L, Dierks T, Barta S, Poustka F, Psychopathology 2002 July:35: 234-40. PMID: 12239440
• Survey of Patients? Views of Domiciliary Nebuliser Treatment for Chronic Lung Disease - a patients’ perspective on home nebulisers.  
  Barta S, Crawford A, Roberts M, Respiratory Medicine 2002 June:96:375-81. PMID: 12117035
• Intensity dependance of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects.  
  Dierks T, Barta S, Demisch L, Schmeck K, Englert E, Kewitz A, Maurer K, Poustka F, Psychopharmacology 1999 Sept:146:101-7. PMID: 10485971
• Join now to see all

Abstracts/Posters

• Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 106
  Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• ARL-IPI – A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab-Era.
  Barta SK, Xue X, Wang D, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Boue F, Wilson W, Wyen C, Dunleavy K, Sparano JA, ASH Annual Meeting, Atlanta
• Relationship between Intensity Dependence of Auditory Evoked Potentials and Impulsive and Aggressive Personality Traits.
  Barta S, Dierks T, Demisch L, Schmeck K, Englert E, Maurer K, Poustka F, Brain Topography 1997 Sept:10: 167-8
• Do African Patients accept and adhere to HAART?
  Lomax N, Wheeler H, Barta SK, Leventis P, Chilton D, Adewakun A, Fakoya A, 7th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland
• Primary lung lymphomas: A clinicopathologic analysis of 61 cases, focusing on immunophenotype, cytogenetics and molecular genetics.
  Kotsali P, Barta SK, Teruya-Feldstein J, Hamlin PA, Fillipa DA, Meeting Abstract: 1140. Modern Pathology 2007 Mar:20: 249A-249A
• Pooled Analysis of AIDS-Malignancy Consortium (AMC) Trials Evaluating Rituximab plus either CHOP or Infusional EPOCH Chemotherapy in HIV-Associated Non-Hodgkin’s Lymph...
  Barta SK, Lee JY, Sparano JA, Kaplan LD, Noy A, American Society for Hematology (ASH) Annual Meeting December 2010, Orlando, Fl
• Synergy of Sequential and Concurrent Administration of a Deglycosylated Ricin A Chain- containing Combined Anti-CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabin...
  Barta SK, Zou Z, Schindler J, Bhagat T, Ghetie V, Vitetta SD, Verma A, American Society for Hematology (ASH) Annual Meeting December 2011, San Diego, CA
• A Pooled Analysis of Treatment Factors Associated with Outcomes in 1144 Patients with HIV Associated Lymphoma.
  Barta SK, Xue X, Tamari R, Lee HY, Mounier N, Ribera JM, Spina R, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Sparano JA, ASCO Meeting Abstracts 2012;30:8005, American Society for Clinical Oncology (ASCO) Annual Meeting
• A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors on Clinical Outcomes.
  Barta SK, Xue X, Wang D, Tamrari, R, Mounier N, Lee JL, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli M, Weiss R, Galicier L, Boue F, Wilson W, Wyen C, Navarro JT, D..., ASH Annual Meeting 2012, Atlanta
• Join now to see all

Lectures

• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinica... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic le... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all